KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Net Margin for 8 consecutive years, with 2.68% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1379.0% to 2.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7.01% through Dec 2025, down 1250.0% year-over-year, with the annual reading at 7.02% for FY2025, 1251.0% down from the prior year.
  • Net Margin hit 2.68% in Q4 2025 for Castle Biosciences, down from 0.6% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 11.11% in Q4 2024 to a low of 91.7% in Q1 2022.
  • Historically, Net Margin has averaged 24.74% across 5 years, with a median of 15.0% in 2021.
  • Biggest five-year swings in Net Margin: plummeted -7294bps in 2022 and later soared 6600bps in 2024.
  • Year by year, Net Margin stood at 53.44% in 2021, then decreased by -1bps to 53.78% in 2022, then soared by 93bps to 3.9% in 2023, then soared by 385bps to 11.11% in 2024, then plummeted by -124bps to 2.68% in 2025.
  • Business Quant data shows Net Margin for CSTL at 2.68% in Q4 2025, 0.6% in Q3 2025, and 5.29% in Q2 2025.